Mangalam Drugs & Organics Ltd has disclosed ongoing defaults on cash credit facilities totaling Rs 15.57 crore across two major lenders. The defaults, which originated in October 2025, remain unresolved as of September 2026. Management is currently negotiating repayment terms, but the liquidity strain remains a primary concern for investors monitoring the firm's operational stability and debt obligations.
Mangalam Drugs & Organics Reports Continued Bank Loan Defaults of Rs 15.57 Crore
Total overdue amount: Rs 15.57 crore.
Duration of default: Originating from October 2025.
Reader Takeaway: Persistent debt defaults signal liquidity strain; monitor management's repayment timeline and potential credit rating impacts closely.
What just happened
Mangalam Drugs & Organics Ltd has issued a formal disclosure under SEBI LODR regulations regarding unpaid cash credit obligations. As of September 14, 2026, the company holds Rs 9.51 crore in overdue debt with the Bank of Maharashtra and Rs 6.06 crore with the Bank of Baroda. These defaults initially occurred in mid-October 2025 and have remained outstanding for nearly 12 months.
Why this matters
The prolonged nature of these defaults raises significant questions about the company’s current working capital cycle and cash flow management. For shareholders, this represents a material risk to financial health, as persistent defaults often lead to restrictive covenants, potential credit rating downgrades, and increased borrowing costs, all of which weigh on future profitability.
What changes now
The company is currently in discussions to arrange for the repayment of these dues. While the formal disclosure provides transparency, the immediate focus for the market will be the timeline for resolution. Investors should watch for any further stock exchange filings confirming settlement or formal restructuring agreements with the involved lenders.
Risks to watch
The primary risk is the potential for further liquidity constraints. If the company fails to settle these obligations promptly, it may face legal actions from creditors or regulatory scrutiny under bankruptcy frameworks. Additionally, any negative impact on credit ratings will likely limit the company's ability to secure fresh capital to fund its day-to-day pharmaceutical operations.
What to track next
Watch for subsequent BSE filings detailing the settlement of these accounts. Investors should also pay close attention to quarterly financial results for indications of improved cash generation or debt-servicing capability.